University of Alabama at Birmingham, 1900 University Blvd, THT 422, Birmingham, AL 35294, USA.
Medical University of South Carolina, Charleston, SC, USA.
J Cyst Fibros. 2021 May;20(3):399-401. doi: 10.1016/j.jcf.2020.12.011. Epub 2021 Jan 19.
Infertility and subfertility are commonly faced by females with cystic fibrosis (FwCF) and resulting in decreased contraceptive use and increased utilization of reproductive technologies. Elexacaftor-tezacaftor-ivacaftor (ETI) is a CFTR modulator that affects common causes of subfertility. Two CF centers conducted a retrospective chart review on females with CF who were receiving ETI and became pregnant. We analyzed obstetrical-gynecological history, genotype, and clinical response to ETI therapy. Fourteen FwCF on ETI became pregnant. Half (7) of the FwCFs were previously attempting to conceive, but only three were using contraceptives. Four FwCF had a history of infertility; two were reconsidering use of reproductive technologies (IUI). Patients achieved conception at mean 8 weeks after initiating ETI. ETI may lessen CF-associated factors that affect fertility; however, its exact mechanism is unknown. This warrants counseling on contraceptive use and family planning prior to initiation of therapy and at routine intervals while utilizing ETI.
不育和不孕是囊性纤维化女性（FwCF）常见的问题，这导致了避孕措施的减少和生殖技术的使用增加。依伐卡托泰沙库巴曲（ETI）是一种 CFTR 调节剂，可影响不孕的常见原因。两个 CF 中心对接受 ETI 并怀孕的 CF 女性进行了回顾性图表审查。我们分析了妇产科病史、基因型和对 ETI 治疗的临床反应。14 名接受 ETI 的 FwCF 怀孕。一半（7 名）的 FwCF 此前正在尝试怀孕，但只有 3 名使用了避孕药具。4 名 FwCF 有不孕史；其中 2 名正在重新考虑使用生殖技术（IUI）。患者在开始 ETI 后平均 8 周受孕。ETI 可能减轻影响生育的 CF 相关因素；然而，其确切机制尚不清楚。这需要在开始治疗前和使用 ETI 的常规间隔期间进行避孕和计划生育咨询。
